男用和女用临床前避孕方法的研发。
Preclinical contraceptive development for men and women.
机构信息
Contraception Research Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Department of Molecular Biosciences, Northwestern University, Evanston, IL, USA.
出版信息
Biol Reprod. 2020 Aug 4;103(2):147-156. doi: 10.1093/biolre/ioaa076.
This manuscript endeavors to present research considerations for the preclinical development of non-hormonal contraceptives. Topics include (1) how advances in genomics and bioinformatics impact the identification of novel targets for non-hormonal contraception, (2) the importance of target validation prior to investment in a contraceptive development campaign, (3) considerations on targeting gametogenesis vs gamete maturation/function, (4) how targets from the male reproductive system are expanding women's options for 'on demand' contraception, and (5) some emerging non-hormonal methods that are not based on a specific molecular target. Also presented are ideas for developing a pipeline of non-hypothalamic-pituitary-gonadal-acting contraceptives for men and women while balancing risk and innovation, and our perspective on the pros and cons of industry and academic environments on contraceptive development. Three product development programs are highlighted that are biologically interesting, innovative, and likely to influence the field of contraceptive development in years to come.
这篇手稿旨在为非激素避孕药具的临床前开发提出研究考虑因素。主题包括：（1）基因组学和生物信息学的进步如何影响非激素避孕药具的新靶标的识别；（2）在投资避孕开发活动之前，目标验证的重要性；（3）关于配子发生与配子成熟/功能靶向的考虑；（4）男性生殖系统的靶标如何扩大女性对“按需”避孕的选择；（5）一些新兴的非激素方法不是基于特定的分子靶标。还提出了一些想法，即开发一种针对男性和女性的非下丘脑-垂体-性腺作用的避孕药具的管道，同时平衡风险和创新，以及我们对避孕开发的行业和学术环境的优缺点的看法。强调了三个具有生物学意义、创新性且可能在未来几年影响避孕开发领域的产品开发计划。
Zotero 插件